Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_assertion type Assertion NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_head.
- NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_assertion description "[Azacitidine gives encouraging results in Ph-negative MPN having progressed to AML or MDS, but response duration is short, and consolidation treatments have to be evaluated.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_provenance.
- NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_assertion evidence source_evidence_literature NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_provenance.
- NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_assertion SIO_000772 20664061 NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_provenance.
- NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_assertion wasDerivedFrom befree-20140225 NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_provenance.
- NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_assertion wasGeneratedBy ECO_0000203 NP800621.RA_1xDU08G13NG9pCymPxqJnbbOuWaaQc4CWorvhf3LWI130_provenance.